StockDuty ← Dashboard Oct 02, 2026 09:45 PM ET
SignalEU/UK

FDA extends review for Novo Nordisk's denecimig for hemophilia A

FDA review extension delays Novo Nordisk's denecimig hemophilia A timeline.

FDA review extension delays Novo Nordisk's denecimig hemophilia A timeline.
FDA review extension delays Novo Nordisk's denecimig hemophilia A timeline. — impact context not separately stored; see What changed.
Sources